- Allergy
- Aspergillosis
- B19 parvovirus
- Bacterial infections
- Blastomycosis
- Cancers - overview
- Candidiasis
- Cardiomyopathy
- Coccidioidomycosis
- Cryptococcus
- Cryptosporidiosis
- Cytomegalovirus (CMV) - overview
- Cytomegalovirus (CMV) - key research on treatment
- Cytomegalovirus (CMV) - key research on prophylaxis
- Cytomegalovirus (CMV) - references
- Depression
- Diabetes
- Entamoeba histolytica
- Giardia lamblia
- Gingivitis
- Guillain-Barré syndrome
- Gynaecomastia (breast enlargement)
- Hairy leukoplakia
- Hepatitis A
- Hepatitis B
- Hepatitis C - overview
- Hepatitis C - key research
- Hepatitis C - references
- Herpes simplex
- Histoplasmosis
- HIV-associated dementia - overview
- HIV-associated dementia - key research
- HIV-associated dementia - references
- HIV-associated salivary disease
- Hodgkin's disease
- Human herpes virus 6
- Human papilloma virus
- Isosporiasis
- Kaposi's sarcoma - overview
- Kaposi's sarcoma - key research
- Kaposi's sarcoma - references
- Lactic acidosis / acidaemia
- Leishmaniasis
- Lung cancer
- Lymphocytic interstitial pneumonitis
- Malaria
- Microsporidiosis
- Molluscum contagiosum
- Multicentric Castleman's disease
- Mycobacterium avium intracellulare (MAI) - overview
- Mycobacterium avium intracellulare (MAI) - key research
- Mycobacterium avium intracellulare (MAI) - references
- Mycobacterium haemophilum
- Mycobacterium kansasii
- Neuropathy
- Neutropenia
- Non-Hodgkin's lymphoma
- Osteonecrosis
- Osteoporosis
- Pancreatitis
- Pelvic inflammatory disease
- Penicilliosis
- Persistent generalised lymphadenopathy
- Pneumocystis pneumonia (PCP) - overview
- Pneumocystis pneumonia (PCP) - prevention & prophylaxis key research
- Pneumocystis pneumonia (PCP) - treatment key research
- Pneumocystis pneumonia (PCP) - references
- Progressive multifocal leukoencephalopathy (PML)
- Psoriasis
- Pulmonary arterial hypertension
- Q fever
- Renal (kidney) disease
- Salmonellosis
- Schistosomiasis and other worm and fluke infections
- Seborrhoeic dermatitis
- Syphilis
- Testicular cancer
- Testosterone deficiency
- Thrombocytopenia
- Thrombotic thrombocytopenic purpura
- Tinea
- Toxoplasmosis - overview
- Toxoplasmosis - treatment key research
- Toxoplasmosis - prophylaxis key research
- Toxoplasmosis - references
- Tuberculosis
- Ulcers
- Vacuolar myelopathy
- Varicella zoster virus
- Wasting syndrome - overview
- Wasting syndrome - key research
- Wasting syndrome - references
Penicilliosis
Penicilliosis is caused by a fungus called Penicillium marneffei. The fungus is widespread in south-east Asia and southern China, but was rarely reported to cause disease before the beginning of the AIDS epidemic in the region. The infection has also been seen in migrants from this region, and in HIV-positive travellers returning from the region.
In Thailand, penicilliosis is one of the most common AIDS-related opportunistic illnesses. There has been a recent case report of HIV-related penicilliosis in India.
Penicilliosis is seen more commonly during the rainy season in Asia, but the precise route of transmission is unknown.
Symptoms
The most common symptom of penicilliosis is a skin rash, which takes the form of small bumps on the skin, often with ulceration on the bump. The rash normally occurs on the upper part of the body, including the face and scalp.
The other common symptoms of penicilliosis are cough, fever, anaemia, weight loss and shortness of breath. A chest X-ray will reveal pulmonary infiltrates if the lungs are affected.
Penicilliosis rarely develops in individuals with CD4 cell counts above 50 cells/mm3, so it is a symptom of advanced immune suppression. It can be diagnosed by culture from blood or from a scraping taken from a skin lesion (if the rash is present). No antigen test is yet available.
Treatment
Antifungal therapy with amphotericin B at 0.6 - 1.0mg/kg per day for two weeks has been used successfully, but the side effects can be difficult to tolerate. Little research into treatment with alternative antifungals such as ketaconazole and itraconazole has been reported, although p. Marneffei has been shown to be sensitive to both drugs in the test tube. Generally, induction treatment with amphotericin will be followed by maintenance treatment with itraconazole (200mg per day). Suppressive treatment will be necessary for as long as the immune system remains severely impaired, but no guidelines currently exist for discontinuing suppressive treatment after immune reconstitution due to HAART.
The initiation of HAART without antifungal treatment is unlikely to be successful, since immune reconstitution may take many months, and in the meantime p. Marneffei may have caused respiratory failure (the most common cause of death associated with this fungal infection).
References
Li PC etal. Penicillium marneffei: indicator disease for AIDS in South East Asia. AIDS 6: 240-241, 1992. Shah K et al. Disseminated penicilliosis: AIDS defining illness (report of an index case from Maharashtra province of India). Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 903, 2003.
latest aidsmap news
- 'ART as prevention tool' policy announced for British Columbia
- <i>The Lancet</i>: HIV is a global disaster
- Important changes to nevirapine dosing advice made by FDA
- Fatty liver in patients with HIV associated with metabolic abnormalities
- Most HIV infections in Zambia and Rwanda happen in marriage: prevention programmes for couples recommended
- HIV-positive Caribbean people in the UK experience high levels of stigma
- Poverty and unemployment common amongst HIV-positive Londoners
- Risk of death for people with HIV now similar to that seen in the general population
- Simple, cheap test an accurate measure of hardening of the arteries in patients with HIV
- Asymptomatic anal HPV infection more common than thought in heterosexual men
